drugset / Trial / NCT01258816
The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
Phase 1
Completed
43 enrolled
Clavis Pharma
CardiaBase · collabLearn & Confirm · collabSyneos Health · collabTheradex · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to investigate the pharmacokinetics (PK) and cardiac properties of elacytarabine in patients with relapsed or refractory Acute Myeloid Leukaemia (AML). The efficacy and tolerability of elacytarabine will also be assessed.
Timeline
- Start
- 2010-10
- Primary completion
- 2013-05
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elacytarabine | Small molecule | 2000 mg/m2 | Intravenous |